Strategies for designing clinical trials for oligonucleotide therapeutics

Drug Discovery Today

Volumn 9, Issue 21, 2004, Pages 918-923

  Wacheck, Volker ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Biochemistry; Correlative studies; Drug Discovery; Maximum tolerated dose; Minimal effective dose; Optimal biological dose; Pharmaceutical Science; Surrogate endpoints; Techniques Methods

Indexed keywords

BIOLOGICAL MARKER; IMMUNOLOGIC AGENT; RECOMBINANT DNA;

CLINICAL TRIAL; CORRELATION ANALYSIS; DNA RECOMBINATION; DOSE RESPONSE; DOWN REGULATION; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; GENE CONTROL; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN GENOME; IN SITU HYBRIDIZATION; MOLECULAR MECHANICS; ONCOLOGY; REVIEW; SENSITIVITY ANALYSIS; SIDE EFFECT;

CLINICAL TRIALS; HUMANS; OLIGONUCLEOTIDES; RESEARCH DESIGN;

EID: 6344260319     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(04)03263-5     Document Type: Review

References (28)

1. Workman P. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones. Cancer Chemother. Pharmacol. 52:(Suppl. 1):2003;S45-S56
2. Opalinska J.B., Gewirtz A.M. Nucleic-acid therapeutics: basic principles and recent applications. Nat. Rev. Drug Discov. 1:2002;503-514
3. Kurreck J. Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem. 270:2003;1628-1644
4. Burgstaller P., et al. Aptamers and aptazymes: accelerating small molecule drug discovery. Curr. Opin. Drug Discov. Devel. 5:2002;690-700
5. Klinman D.M. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 4:2004;249-258
6. Bishop M.R., et al. Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J. Clin. Oncol. 14:1996;1320-1326
7. Jansen B., Zangemeister-Wittke U. Antisense therapy for cancer - the time of truth. Lancet Oncol. 3:2002;672-683
8. Fox E., et al. Clinical trial design for target-based therapy. Oncologist. 7:2002;401-409
9. Hoekstra R., et al. Clinical trial design for target-specific anticancer agents. Invest. New Drugs. 21:2003;243-250
10. Saijo N., et al. Translational and clinical studies of target-based cancer therapy. Int. J. Clin. Oncol. 8:2003;187-192
11. Gobburu J.V., Marroum P.J. Utilisation of pharmacokinetic-pharmacodynamic modelling and simulation in regulatory decision-making. Clin. Pharmacokinet. 40:2001;883-892
12. Hargreaves R. Imaging substance P receptors (NK1) in the living human brain using positron emission tomography. J. Clin. Psychiatry. 63:(Suppl. 11):2002;18-24
13. Bergstrom M., et al. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol. Psychiatry. 55:2004;1007-1012
14. Frank R., Hargreaves R. Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov. 2:2003;566-580
15. Cohen M.H., et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin. Cancer Res. 10:2004;1212-1218
16. Blue J.W., Colburn W.A. Efficacy measures: surrogates or clinical outcomes? J. Clin. Pharmacol. 36:1996;767-770
17. Biomarker Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69:2001;89-95
18. Jansen B., et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet. 356:2000;1728-1733
19. Rolan P., et al. Use of biomarkers from drug discovery through clinical practice: report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development. Clin. Pharmacol. Ther. 73:2003;284-291
20. Lesko L.J., Atkinson A.J. Jr. Use of biomarkers and surrogate endpoints in drug development and regulatory decision-making: criteria, validation, strategies. Annu. Rev. Pharmacol. Toxicol. 41:2001;347-366
21. Bichsel V.E., et al. Cancer proteomics: from biomarker discovery to signal pathway profiling. Cancer J. 7:2001;69-78
22. Mani S., Ratain M.J. New Phase I trial methodology. Semin. Oncol. 24:1997;253-261
23. Storer B.E. Design and analysis of Phase I clinical trials. Biometrics. 45:1989;925-937
24. van Kesteren C., et al. Pharmacokinetic-pharmacodynamic guided trial design in oncology. Invest. New Drugs. 21:2003;225-241
25. Collins J.M., et al. Potential roles for preclinical pharmacology in Phase I clinical trials. Cancer Treat. Rep. 70:1986;73-80
26. O′quigley J., et al. Continual reassessment method: a practical design for Phase 1 clinical trials in cancer. Biometrics. 46:1990;33-48
27. Thall P.F., Lee S.J. Practical model-based dose-finding in Phase I clinical trials: methods based on toxicity. Int. J. Gynecol. Cancer. 13:2003;251-261
28. Kopec J.A., et al. Randomized discontinuation trials: utility and efficiency. J. Clin. Epidemiol. 46:1993;959-971